Organon - Search News

Roivant, Organon

Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, and then selling them for big returns.

GlobalData on MSN · 5d

Organon makes $1.2bn play for Roivant’s immuno-dermatology subsidiary

As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis.

Reuters · 6d

Organon to buy Roivant's dermatology unit for up to $1.2 billion

However, Organon was down 1.4%. Dermavant's Vtama cream, approved by the U.S. Food and Drug Administration in May 2022, treats psoriasis, a common long-term inflammatory skin disease. The FDA is also reviewing an application to expand the use of the drug ...

Business Insider · 6d

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an

Organon: A Surprising Deal

Organon shares have stabilized in recent times, with gradual debt reduction and structural growth allowing for a valuation re ...

FiercePharma7d

Organon pays up to $1.2B to acquire Dermavant and its steroid-free skin cream Vtama

With its latest acquisition, women’s health outfit Organon is bringing its dermatology business to the U.S. with a ...

Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B

Organon & Co (NYSE:OGN) has agreed to acquire Roivant Sciences Ltd’s (NASDAQ:ROIV) Dermavant Sciences Ltd, which is focused ...

NJBIZ5d

Organon to acquire Dermavant in $1.2B deal

The Roivant company is dedicated to developing and commercializing innovative therapeutics in immune-dermatology.

pharmaphorum6d

Organon makes dermatology play with $1.2bn Dermavant buyout

Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, ...

Barron's2d

Organon & Co.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

Assessing Organon’s Strategic Acquisition of Dermavant: A Balanced Hold Recommendation Amid Growth and Challenges

Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Organon (OGN – Research Report), retaining the price target of ...

Zawya2d

Organon and Forge Society join forces to promote family planning awareness in Egypt

At the heart of the event was Organon’s commitment to empowering women through access to safe and effective family planning ...

Roivant's Sale Of Dermavant To Organon: A Strategic Win-Win In Atopic Dermatitis

Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Related topics